Medical Marijuana Product Types: Flower, Edibles, Tinctures, and Concentrates

Walk into a licensed dispensary for the first time and the product menu can read like a foreign language — percentages, ratios, extraction methods, and dose notations stacked across categories that didn't exist in the same form a decade ago. The four foundational product types in the medical cannabis market are flower, edibles, tinctures, and concentrates, and each one reaches the body through a distinct mechanism with its own onset window, duration profile, and risk considerations. Understanding these differences is practical medicine, not trivia — the wrong product choice can mean either no therapeutic effect or an unexpectedly intense one.

Definition and Scope

Medical cannabis products are classified primarily by form factor and delivery method, which together determine how cannabinoids — principally THC and CBD — enter the bloodstream. The U.S. Food and Drug Administration has approved exactly three cannabis-derived or cannabis-related medications as of the federal record: Epidiolex (cannabidiol), Marinol (dronabinol), and Syndros (dronabinol), detailed at FDA-approved cannabis-based medications. State-licensed dispensaries, however, operate under individual state pharmacy and health department frameworks that permit a much wider array of formulations.

The four primary categories recognized across state dispensary regulations are:

1. Flower — the dried, cured cannabis plant material, consumed by smoking or vaporizing
2. Edibles — food or beverage products infused with cannabis extract, consumed orally
3. Tinctures — liquid cannabis extracts, typically alcohol- or oil-based, administered sublingually or orally
4. Concentrates — high-potency extracts (wax, shatter, oil, rosin) consumed by dabbing, vaporization, or as an ingredient in other products

Each category sits under state-specific labeling and potency disclosure rules. California's Bureau of Cannabis Control, for instance, requires all retail cannabis products to display total THC and CBD content in milligrams per unit, not merely percentages — a standard that has become a model for other state programs.

How It Works

The mechanism of action for each product type hinges on the route of absorption, which directly governs onset speed and dosing precision.

Flower and vaporized concentrates bypass the digestive system entirely. Inhaled cannabinoids cross the lung's alveolar membrane and reach peak plasma concentration in roughly 3 to 10 minutes, according to the National Institute on Drug Abuse (NIDA). This rapid onset is useful for acute symptom management — breakthrough pain, nausea, or anxiety spikes — but the duration is comparatively short, typically 1 to 3 hours.

Edibles travel through the gastrointestinal tract, where THC is converted by the liver into 11-hydroxy-THC before entering circulation. This hepatic first-pass metabolism produces a compound that crosses the blood-brain barrier more readily than inhaled THC, resulting in a more intense and prolonged effect — onset of 30 to 120 minutes and duration of 4 to 8 hours. The variability in onset is the most clinically significant feature of this route; a patient who doesn't feel an effect at 45 minutes and re-doses can easily overshoot. A standard edible dose in most regulated state markets is defined as 10 mg of THC per serving, with packaging required to contain no more than 100 mg total in adult-use contexts — though medical patient allowances vary by state.

Tinctures occupy a middle ground. Placed under the tongue and held for 60 to 90 seconds, they allow partial sublingual absorption directly into capillaries, with onset around 15 to 45 minutes. The portion that is swallowed follows the same GI route as edibles. This dual pathway makes tinctures useful for titration — small, measurable doses in a 1 mL dropper format allow fine-grained adjustment, which is why they appear frequently in pediatric epilepsy protocols.

Concentrates can reach THC concentrations of 60% to 90% by weight, compared to flower, which typically ranges from 10% to 30% THC. The cannabinoids and their effects embedded in these products are chemically identical to those in flower — the difference is simply density and, by extension, the margin for dosing error.

Common Scenarios

The product type selected in a clinical context often maps to the symptom profile being addressed:

• Chronic pain and inflammation: Tinctures and edibles dominate here due to their longer duration window, reducing the need for repeated dosing. Medical marijuana for chronic pain programs in states like New York and Pennsylvania frequently list oils and capsules as preferred formats.
• Chemotherapy-induced nausea: Inhaled flower or fast-acting vaporized concentrates are often chosen because nausea can prevent oral consumption; the FDA-approved oral THC drug Marinol was specifically developed to address this gap, though its fixed 5 mg and 10 mg capsule doses offer less flexibility than dispensary tinctures.
• Epilepsy and seizure disorders: The FDA-approved CBD medication Epidiolex is an oral solution at a concentration of 100 mg/mL — structurally a pharmaceutical tincture. State programs for epilepsy often mirror this preference for precise liquid dosing.
• Sleep disorders: Edibles timed 90 minutes before sleep onset are a common pattern, exploiting the longer duration window described above.

Decision Boundaries

No single product type is universally superior. The choice depends on four intersecting variables:

1. Onset requirement — acute symptom relief favors inhalation; sustained effect favors oral routes
2. Pulmonary health — patients with respiratory conditions should avoid combustion; vaporization reduces (but does not eliminate) inhalation risk, per safety and risk context
3. Dose control precision — tinctures and capsules allow milligram-level accuracy; flower and concentrates require more experiential calibration
4. Regulatory access — not all product types are legal in every state program; state-by-state program differences determine which formats a patient can legally obtain on their card

Concentrates warrant particular attention in a safety frame. The National Academies of Sciences, Engineering, and Medicine's 2017 report The Health Effects of Cannabis and Cannabinoids identified limited evidence specifically on high-potency concentrate use, noting that the product category had outpaced the research literature. For patients new to medical cannabis, starting with a lower-potency format — flower at a known THC percentage, or a calibrated tincture — establishes a baseline before introducing concentrate products. Side effects including tachycardia, anxiety, and temporary cognitive impairment scale with dose and potency, making the choice of product type inseparable from the question of therapeutic risk.